Figures
Abstract
Background
Friedreich's ataxia (FRDA), the most common recessive ataxia in Caucasians, is due to severely reduced levels of frataxin, a highly conserved protein, that result from a large GAA triplet repeat expansion within the first intron of the frataxin gene (FXN). Typical marks of heterochromatin are found near the expanded GAA repeat in FRDA patient cells and mouse models. Histone deacetylase inhibitors (HDACIs) with a pimelic diphenylamide structure and HDAC3 specificity can decondense the chromatin structure at the FXN gene and restore frataxin levels in cells from FRDA patients and in a GAA repeat based FRDA mouse model, KIKI, providing an appealing approach for FRDA therapeutics.
Methodology/Principal Findings
In an effort to further improve the pharmacological profile of pimelic diphenylamide HDACIs as potential therapeutics for FRDA, we synthesized additional compounds with this basic structure and screened them for HDAC3 specificity. We characterized two of these compounds, 136 and 109, in FRDA patients' peripheral blood lymphocytes and in the KIKI mouse model. We tested their ability to upregulate frataxin at a range of concentrations in order to determine a minimal effective dose. We then determined in both systems the duration of effect of these drugs on frataxin mRNA and protein, and on total and local histone acetylation. The effects of these compounds exceeded the time of direct exposure in both systems.
Citation: Rai M, Soragni E, Chou CJ, Barnes G, Jones S, Rusche JR, et al. (2010) Two New Pimelic Diphenylamide HDAC Inhibitors Induce Sustained Frataxin Upregulation in Cells from Friedreich's Ataxia Patients and in a Mouse Model. PLoS ONE 5(1): e8825. https://doi.org/10.1371/journal.pone.0008825
Editor: Antoni L. Andreu, Hospital Vall d'Hebron, Spain
Received: October 24, 2009; Accepted: December 31, 2009; Published: January 21, 2010
Copyright: © 2010 Rai et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This work was supported by grants from GoFar and the Fondazione CRT (Italy), from the Kyle Bryant translational research award, the Association Française Ataxie de Friedreich (AFAF), the Fonds de la Recherche Scientifique - FNRS and the Fonds Erasme - Jean Van Damme to MP; from the Kyle Bryant translational research award to JRR; from the Friedreich's Ataxia Research Alliance (FARA), the National Ataxia Foundation (NAF), the National Institutes of Neurological Disorders and Stroke (NINDS) to JMG. Repligen Corporation partly funded the work described in this paper. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing interests: Repligen Corporation has acquired a license from the Scripps Research Institute for the development of the pimelic diphenylamide HDAC inhibitors first synthesized in the lab of JMG. Repligen filed for patenting the molecules described in this manuscript. GB, SJ and JRR are employees of Repligen and JMG is a consultant for Repligen. This corporate involvement does not alter the authors' adherence to all the PLoS ONE policies on sharing data and materials.
Introduction
Friedreich's ataxia (FRDA) is the most common of the early-onset autosomal recessive ataxias in Caucasians. In addition to progressive neurological disability, FRDA causes a hypertrophic cardiomyopathy and an increased risk of diabetes mellitus. Skeletal abnormalities such as kyphoscoliosis and pes cavus are common. The first symptoms usually are noticed around the time of puberty [1], [2]. As is the case for almost all neurodegenerative diseases, no proven treatment that can stop the progression of FRDA is now known. FRDA is caused by severely reduced levels of frataxin [3], a highly conserved mitochondrial protein, that result from a large GAA triplet repeat expansion within the first intron of the frataxin gene (FXN). In vitro and in vivo in bacterial plasmids the expanded repeat can adopt a triple helical structure that directly interferes with transcriptional elongation [4]. However, the discovery that long GAA repeats suppress the expression of a nearby reporter gene in transgenic mice in a manner similar to position effect variegation (PEV) observed in Drosophila pointed to a role of epigenetic mechanisms in the pathogenesis of FRDA [5], [6], [7]. PEV results in the silencing of a gene located near a heterochromatic region because of the spreading of heterochromatin into the gene itself. This phenomenon does not occur in all cells, hence the term “variegation”, but nevertheless leads to an overall downregulation of the involved gene at the tissue and organ level. In agreement with this hypothesis, the typical marks of heterochromatin, such as DNA methylation and histone deacetylation, are found near the expanded GAA repeat both in FRDA patients' cells and in mouse models [6], [7], [8], [9]. Based on these observations, we speculated that histone deacetylase (HDAC) inhibitors (HDACIs) might reverse FXN silencing by directly increasing histone acetylation on the FXN gene, leading to chromatin decondensation and active transcription. The dynamic interplay between histone acetylation, performed by histone acetyltransferases (HATs) and deacetylation, catalyzed by HDACs, is indeed a central mechanism to regulate gene expression, with increased acetylation associated with an open chromatin conformation and active genes [10]. Eighteen HDACs (more strictly, protein deacetylases) have been identified in the human genome, including the zinc-dependent HDACs (class I, class II, and class IV), and the NAD+-dependent protein deacetylase enzymes (class III, or sirtuins) [11]. Accordingly, a diverse class of compounds that inhibit HDACs has been developed. Despite a potential widespread effect of HDAC inhibition on key processes as cellular differentiation and development, many of these compounds are well tolerated in humans and some of them show therapeutic promise in a wide range of diseases, including cancer, metabolic and neurological diseases [12], [13]. Target specificity and kinetic properties of HDACIs probably define the spectrum of genes whose expression they affect, explaining why a catastrophic general deregulation of gene expression is not observed with their use.
We found that a commercially available HDACI (BML-210), and derivatives we have synthesized (pimelic diphenylamides), relieve repression of the FXN gene in lymphoid cell lines derived from FRDA patients, in primary lymphocytes from donor FRDA patient blood, and in the brain and heart of a mouse model for FRDA [8], [9]. Unexpectedly, we also found that only members of the pimelic diphenylamide family of HDAC inhibitors increase FXN gene expression, and many common and highly active HDAC inhibitors, including the hydroxamates trichostatin A (TSA) and suberoylanilide hydroxamic acid (SAHA), are inactive. Pimelic diphenylamide HDACIs specifically target class I HDACs, with the highest inhibitory effect on HDAC3 [14]. They are further characterized by a slow-on slow-off kinetics, leading to a more persistent histone hyperacetylation than induced by other HDACIs, including very potent molecules like suberoylanilide hydroxamic acid (SAHA).
In an effort to further improve the pharmacological profile of pimelic diphenylamide HDACIs as potential therapeutics for FRDA, we synthesized additional compounds with this basic structure and screened them for HDAC3 specificity. Here we report the characterization of two of these compounds in FRDA patients' peripheral blood lymphocytes and in the KIKI mouse model. Our results support the development of a therapeutic approach based on pimelic diphenylamide HDACIs for FRDA and provide information for the design of future human trials of these drugs [14].
Results
Two Novel Pimelic Diphenylamides with Histone Deacetylase Inhibitor Activity
Two compounds, similar in structure to each other and to compound 106 N1-(2-aminophenyl)-N7-p-tolylheptanediamide), but having a different pattern of HDAC isotype inhibition, were synthesized: 109: N-(6-(2-aminophenylamino)-6-oxohexyl)-4-methylbenzamide and 136 N-(6-(2-amino-4-fluorophenylamino)-6-oxohexyl)-4-methylbenzamide (Figure 1). Purified recombinant HDAC enzymes were used with a fluorescent substrate to determine IC50 and Ki values (see Methods S1). The Ki values for HDAC1 and HDAC3, given as a ratio of HDAC1/HDAC3 are: ∼6 fold for 109 and ∼3 fold for 136 Figure 1). Both molecules showed the same slow-on/slow-off inhibition kinetics previously demonstrated for other compounds of the same class (Figures S1 and S2) [15].
The structures of the new compounds 109 and 136 are shown, along with the structures of the previously described compound 106 [9] and of SAHA. For each compound, the IC50 and Ki for HDAC1 and HDAC3 are provided.
Effects of Compounds 136 and 109 in Unstimulated Peripheral Blood Mononuclear Cells from FRDA Patients
We tested compounds 136 and 109 for their ability to upregulate frataxin mRNA in cultures of unstimulated peripheral blood mononuclear cells (PBMC) obtained from FRDA patients. Compound 106 (also called RGFA8) that had previously shown efficacy in this system was used as benchmark positive control. Compound 136 showed a limited effect in this test (Figure 2A), even at the highest tested concentration of 10 µM, when compared to 10 µM compound 106. Frataxin mRNA was not affected by 136 treatment in PBMC samples P1, P2 and P6, and was mildly upregulated in samples P3-P5 and P7, whereas compound 106 increased frataxin mRNA levels by 3.6 fold on average (p<0.001 in all tested patients with compound 106). Conversely, compound 109 was highly active in the whole tested concentration range from 1 to 10 µM (Figure 2B) (p<0.001 in all tested patients with compound 109 at 10 µM), showing an almost linear dose-response relation with the induced frataxin mRNA increase, except in the case of patient P12. This individual is a late-onset, mildly affected FRDA patient, who carries relatively short GAA repeat expansions and has higher baseline frataxin levels than the other patients, suggesting that HDAC inhibition may be more effective when long GAA repeat strongly downregulate FXN expression. Healthy volunteers PBMCs were not overall significantly affected by either treatment, though non-significant fluctuations and a trend toward downregulation by compound 136 were observed (Figure S3). These data are in agreement with our previous observation that no frataxin upregulation is induced by compound 106 in the brain and heart of wild-type mice [8]. They indicate that the upregulation of frataxin levels induced by these compounds in patients' cells is due to an effect on the epigenetic changes caused by the expanded GAA repeat.
A. FXN mRNA levels were measured in RNA from isolated PBMCs from patients (P1–P7) after a 48-hour incubation with either 136 or 106 at 10 µM or DMSO (at 0.1%). Quantitative real-time RT-PCR was used to determine relative FXN levels for each patient condition using GAPDH as a control housekeeping gene. DMSO condition was set to value 1 for each patient. Error is represented as the standard deviation of the mean from 3 determinations. p<0.001 in all tested patients with compound 106. Primary lymphocytes were obtained from donor blood from FRDA patients as described [8]. B. FXN mRNA measurement by quantitative real-time RT-PCR in RNA from isolated PBMCs from patients (P6–P12) after a 48-hour incubation with 109 at 1, 2.5, 5 or 10 µM, or 106 at 10 µM or or 136 at 10 µM or with DMSO (at 0.1%) as control. DMSO condition was set to value 1 for each patient, with GAPDH as reference gene. p<0.001 for P6-7 with compound 109 at 5 and 10 µM and with compound 106; p<0.001 in all conditions for P8-P11 except for P11 condition with compound 136; p<0.001 for P12 only with compound 109 at 10 µM only. C. Representative table of GAA repeat size in tested patients samples. D. PBMCs from patient P13 were treated with either 109 at 10 µM or DMSO for 24, 48 or 72 hours before harvesting. FXN mRNA was determined by quantitative real-time RT-PCR, relative to GAPDH. E. Protein extracts were prepared from harvested cells from panel D. treated with DMSO or 109, and subjected to western blotting with frataxin or GAPDH antibodies. F. Another extraction of PBMC from patient P13 were treated with either 109 at 10 µM or DMSO for 48 hours and harvested after a 6, 12 or 24 hours wash out period. FXN mRNA was determined by real-time RT-PCR and in G., frataxin protein was assessed by western blotting followed by densitometry quantification after the same time points for wash out.
To follow the duration of effect of 109 in PBMC, cells were treated with 10 µM 109 or, as a control, with its dimethylsulfoxide (DMSO)-containing buffer for 24, 48 or 72 hours. Frataxin mRNA increased to 2.4-fold after 24 hours, 2.7-fold after 48 hours and 1.8-fold after 72 hours, as revealed by quantitative RT-PCR (Figure 2D). In a second set of experiments, cells from patient P13 were treated for 48 hours with 10 µM 109 or DMSO. A fraction of cells was collected and another fraction was washed and sub-cultured in regular media without the HDAC inhibitor for further 6, 12, or 24 hours (Figure 2F). Frataxin mRNA levels were still stable 6 hours after removing the drug, they showed an initial decrease at 12 hours and returned to the pre-treatment baseline 24 hours after drug removal. The corresponding increase in frataxin protein, as determined by western blot, occurred more slowly, reaching ∼2 to ∼3.6 fold over baseline (in two separate experiments) at 48 to 72 hours of continuous 109 incubation (Figure 2E and 2G). When the compound was removed after 48 hours of incubation, frataxin protein levels rapidly increased up to ∼6 fold over baseline at 6 hours after the drug washout, and this marked increase was still present at 24 hours (Figure 2G). The increase in FXN gene expression was paralleled by increased histone acetylation, both when determined globally by estimating the ratio between acetylated and total histone H3, and locally near the FXN GAA repeat by quantitating acetylation of histone H4 at lysine 5 (H4K5) by chromatin immunoprecipitation (ChIP) (Figure S3).
Effects of Compounds 109 and 136 in KIKI Mice
We previously showed that homozygous knock-in mice carrying a (GAA)230 repeat in the first intron of the endogenous frataxin gene (fxn), called KIKI mice [16], recapitulate the genetic and epigenetic changes observed in FRDA [9]. We injected a group of KIKI mice (n = 5 per group) with a single subcutaneous dose of 150 mg/kg of compound 136 or with an equivalent volume of vehicle. We sacrificed the mice 24 hours after the injection and found an increase in frataxin mRNA in the brain to wild-type levels. To determine the lowest dose of 136 that could achieve a similar frataxin mRNA increase, we injected KIKI mice with a single subcutaneous dose of 5, 15, 50 or 150 mg/kg of compound 136 (n = 6 or 7 per group) or with vehicle (n = 13). Fxn mRNA significantly increased in the brain (p<0.001) and in the heart (p = 0.009 and 0.008 respectively) only in mice that received 50 or 150 mg/kg (Figure 3A). In the brains of mice from these groups, we observed by chromatin immunoprecipitation (ChIP) an increase in histone acetylation at positions H3K14 and H4K5 in the region of the fxn gene immediately upstream of the inserted GAA repeat (Fig. 3B).
A. Fxn mRNA measurement by quantitative real-time RT-PCR in brain and heart of KIKI mice dosed subcutaneously with 136 at 5 (n = 7), 15 (n = 7), 50 (n = 6) or 150 (n = 6) mg/kg or vehicle (n = 13) as negative control. Fxn levels were relative to RER1 and beta-2 microglobulin (β2M). The Fxn level in vehicle injected KIKI of each tissue was set to 100. All quantifications were done in triplicate and bars indicate s.d. (** p<0.001; * p<0.05). B. Levels of H4K5 and H3K14 acetylation in KIKI mice brain treated with one subcutaneous injection of 50 or 150 mg/kg of 136 compared to vehicle-treated KIKI littermates (n = 4). We performed ChIP experiments with antibodies for murine histones H3 and H4 carrying each modification. Primer pairs corresponded to the first intron of the mouse frataxin gene just upstream of the point of insertion of the GAA repeat in KIKI mice. Relative recovery, determined by qPCR, is expressed in relation to GAPDH and the recovery in samples from vehicle treated KIKI animals is set to 100 for each antibody. Each immunoprecipitation was quantified in triplicate, Error bars are s.e.m.
Compound 109 was also able to correct frataxin deficiency in the brain and heart of KIKI mice 24 hours after a single injection of a 150 mg/kg dose, but not when lower doses were used (data not shown). When followed in time, the frataxin mRNA increase induced by compound 109 in the KIKI mouse could be first detected at 12 hours (n = 4) and reached a maximum at 24 hours (n = 9) in both brain (p<0.001) and heart (p = 0.02) (Figure 4A). Frataxin mRNA levels then showed a decrease at 48 hours and returned to normal levels by 72 hours. The frataxin protein similarly increased at 24 hours and returned to baseline at 72 hours (data not shown). Histone acetylation of residues H3K14 and H4K5 in the region upstream of the GAA repeat, as revealed by ChIP, also increased between 12 and 24 hours after the HDACI injection (Figure 4B). In order to compare this effect on histone acetylation near the GAA repeat with the overall effect of the compound on histone acetylation, we injected a group of wild-type mice (n = 5 per time point) with either vehicle or 109 at 150 mg/kg and estimated total and acetylated histone H3 levels in brain by western blot (Figure 4C). Acetylation increased to a maximum level at 4 hours after injection and totally disappeared at 24 hours. Finally, we determined the levels of compound 109 in the mouse brain and plasma after a single 150 mg/Kg injection and found out that it is totally eliminated before 4 hours (Figure 4D). No acute toxicity signs such as changes in respiration, activity, temperature or lack of sedation were noticed in any of the above experiments, as observed in the open cage behavior.
A. Fxn mRNA measurement by quantitative real-time RT-PCR in brain and heart of KIKI mice dosed subcutaneously with 109 at 150 mg/kg (n = 26) or vehicle (n = 13). Treated mice were sacrificed at one of the mentioned time points: 4, 12, 24, 48 or 72 h. Vehicle treated mice were sacrificed 24 hours after injection. Fxn mRNA levels were relative to RER1 and beta-2 microglobulin (b2M). The Fxn level in vehicle injected KIKI of each tissue was set to 100. All quantifications were done in triplicate and bars indicate s.d. (** p<0.001; * p<0.05). B. Levels of H4K5 and H3K14 acetylation in KIKI mice brain treated with one subcutaneous injection of 150 mg/kg of 109 compared to vehicle-treated KIKI littermates, after 4, 12, 24 or 48 hours (n = 4 for each shown time point). We performed ChIP experiments with antibodies for murine histones H3 and H4 carrying each modification. Primer pairs corresponded to the first intron of the mouse frataxin gene just upstream of the point of insertion of the GAA repeat in KIKI mice. Relative recovery, determined as previously (Fig. 3B) is set to 100 for each residue. Each immunoprecipitation was quantified in triplicate. Error bars are s.e.m. C. Brains from wild-type mice for total histone H3 acetylation and from KIKI mice for specific residues acetylation, injected with either vehicle or with 150 mg/kg of 109, were harvested after a period of 1, 4, 12, 24, 48 or 72 hours (n = 5 per condition) and subjected to western blot with total or acetylated histones H3 antibodies for WT samples or to chromatin immunoprecipitation for KIKI samples. Ratio of acetylated H3 over total H3 is plotted, showing a peak of acetylation at 4 hours. Recovery of specific residues is plotted, showing a plateau between 12 and 24 hours. D. Composite graphic of 109 measures in mouse brain: in black, drug 109 exposure measured in µg/ml; in blue, total histone acetylation from western blot quantification (panel C); in red, fxn RNA as determined by qPCR in panel A.
Because of the discrepancy between patients' PBMCs and KIKI mouse tissues in the relative response to compounds 109 and 136, we compared the effect of HDACi 106, 109 and 136 in splenocytes collected from pooled KIKI or WT mice spleens. Splenocytes are close to PBMCs in terms of cell type composition, both being mostly lymphocytes, allowing to test whether the different response in human vs. mouse was due to a species difference or to a different relative sensitivity to the HDACIs of the tested cell types, mostly lymphocytes in humans vs. central nervous system and heart cells in the mouse. In mouse splenocytes, frataxin mRNA upregulation was significant (p<0.001) only with compounds 106 and 136 (Figure 5), supporting a species difference.
Splenocytes were collected from pooled KIKI spleens (n = 3) or WT spleens. Spleen mononuclear cells were cultured in triplicate for 48 hours with one of HDACi 106, 109 and 136 at 10 µM or with DMSO for KIKI samples. WT samples were cultured in triplicate for 48 hours with. Quantitative real-time RT-PCR was used to determine relative Fxn levels for each condition using RER1 and β2M as control housekeeping genes. DMSO KIKI condition was set to value 1. Error is represented as the standard deviation of the mean from 3 determinations. p<0.001 for 106 and 136 KIKI responses.
Discussion
We generated new pimelic diphenylamide HDACIs to maximize efficacy in upregulating frataxin and to optimize pharmacological properties in view of a future translation to the clinic. The new compounds show the same type of inhibition kinetics and HDAC3 specificity as the previously reported molecules. We selected two of these compounds, 109 and 136, that differ for overall potency and degree of specificity for HDAC3, both being higher for compound 109 (Figure 1), and tested them in FRDA patients' PBMC and in the KIKI mouse model. We then determined in both systems the duration of effect of these drugs on frataxin mRNA and protein, and on total and local (upstream of the GAA repeat) histone acetylation.
In FRDA patients' PBMC, compound 109 was much more potent than compound 136 in upregulating frataxin, supporting the concept that HDAC3 selectivity correlates with this property. A good dose-response correlation could be detected for compound 109, with a 4- to 9-fold upregulation of frataxin mRNA at the highest tested concentration of 10 µM. Rather surprisingly, however, compound 136 turned out to be effective at a threefold lower dose and more consistently in the KIKI mouse model, both in the FRDA target tissues after sub-cutaneous treatment and in in vitro treated splenocytes. At this time we have no definite explanation for such a discrepancy. The similar response of mouse splenocytes (closely related to the PBMCs tested in human patients) and of mouse nervous and cardiac tissue supports the hypothesis of a species difference rather than a cell type difference. It is possible that the mouse and human enzymes have differences in the response to the inhibitor, the inhibition kinetics having been determined with the human enzyme. It is also possible that the compounds differ in pharmacokinetic or metabolic properties in the mouse. Such species differences have to be taken into account in the preclinical development of these drugs.
An important conclusion of this study comes from the analysis of the time course of the effects of these compounds in patients' PBMC and in mice, that long exceeds the time of direct exposure to the drugs. Frataxin mRNA remained elevated in PBMC for at least 12 hours after drug removal and in mice for at least 24 hours after a single subcutaneous injection. In both systems, the time course of frataxin mRNA upregulation paralleled the increase in total and local histone acetylation. These data confirm that HDAC inhibition is a more persistent phenomenon after transient exposure to this category of compounds than to other HDACIs like SAHA [15]. Most importantly, the increase in frataxin protein was the most sustained effect, lasting more than 48 hours after drug dosing in the mouse. It is of note that frataxin protein levels sharply increased in PBMC immediately after drug washout, reaching much higher levels compared to those obtained with continued exposure to the compounds. This finding may be due to inhibition of translation or of some post-transcription RNA processing step by the HDACI [17]. Taken together, these data suggest that intermittent administration of the drug, i.e. less than once daily and possibly as spaced as once or twice a week, may be the dosing regime of choice for the future clinical testing of these drugs. Such regimen would minimize toxic side effects by reducing drug exposure, at the same time allowing sustained upregulation of frataxin protein.
Finally, it is important that this class of HDACIs has not shown any apparent toxicity in this series of experiments, neither in cell culture, nor in the animal studies. These studies were not designed to provide a complete assessment of acute toxicity, however, and complete preclinical testing will be necessary before any human test. Together with the previous studies [8], [9], the present results support the pre-clinical development of pimelic diphenylamide HDACIs as potential therapeutics for FRDA.
Methods
Ethics Statement
Friedreich's ataxia patients donated blood (Human Subjects Protocol approved by the Erasme Hospital ethics committee) with appropriate written informed consent. All animal procedures respected regulations and guidelines of the Belgian state and European Union and were approved by the local ethical committee (CEBEA).
Animal Procedures
GAA knock-in mice were generated and genotyped as described[16]. Age and gender matched WT littermates were used as controls. Mice were treated by a single subcutaneous injection with 150 mg/kg (or other dose when mentioned) of HDACi 109 or HDACi 136 or its equivalent of vehicle. Brain and heart were recovered 24 hours after last injection, or at indicated time.
Primary Lymphocytes Culture
About 40 ml of blood was collected in heparinized Vacutainer tunes (BD Biosciences) and lymphocytes were isolated by density centrifugation using Ficoll – Paque PLUS (GE Healthcare), according to the manufacturer. Lymphoctyes were maintained in RPMI 1640 medium with 2 mM l-glutamine, penicillin / streptomycin and 15% FBS at 37°C in 5% CO2. Cells viability and morphology were monitored by trypan blue exclusion on phase-contrast microscopy. We dissolved compounds 106, 136 and 109 in DMSO and added the solution into the culture medium at the concentrations and for the duration indicated in Figure 2. Controls were treated with the same concentration of DMSO-lacking compounds.
Mouse Splenocytes Culture
Spleens collected from KIKI or WT mice were mashed between 2 glass slides, ground with a 1-mL syringe pestle, then suspended in RPMI 1640 medium supplemented with 2 mM l-glutamine, 15% fetal calf serum and penicillin / streptomycin before filtering through a 75-µm nylon mesh. After washes, red blood cells were removed with lysis buffer (155 mM NH4Cl (pH 7.4), 10 mM NaHCO3, 0.1 mM EDTA). Spleen mononuclear cells were collected, washed, and resuspended before subculturing in triplicate for 48 hours in culture medium containing DMSO (negative control (-)) or one of HDACi 106, 109 and 136 at 10 µM.
Quantitative Real Time PCR
Total RNA was extracted from PBMC and splenocytes by RNeasy Mini Kit (Qiagen). Total RNA from mice brain was extracted by RNeasy Lipid Tissue Mini Kit (Qiagen) as recommended by the manufacturer. RNA from mice heart was extracted by RNeasy Fibrous Tissue Mini Kit (Qiagen). All RNA samples were treated with RNase-Free DNase Set (Qiagen) and quantified afterwards by measuring the optical density (NanoDrop ND-1000 Spectrophotometer, NanoDrop Technologies). Quality and purity of some samples were analyzed by gel electrophoresis on RNA assay chips (Experion System and StdSens analysis kit, BioRad Laboratories). We performed one-step qRT-PCR using MultiScribe Reverse Transcriptase with Power SYBR Green (both from Applied Biosystems). Primers used for FXN were 5′-CAGAGGAAACGCTGGACTCT-3′ and 5′-AGCCAGATTTGCCTTGTTTGG-3′, and primers for Fxn were 5′- CCTGGCCGAGTTCTTTGAAG-3′ and 5′- GCCAGATTTGCTTGTTTGG-3′. Cells RNA was standardized by quantification of GAPDH. Mice brain and heart RNA was quantified relative to RER1 and beta-2 microglobulin (β2M) using qBase 1.3.4 (Jan Hellemans & Jo Vandesompele). These control genes were chosen because they did not show genotype (KIKI vs. wild-type) or treatment-related changes. Data are normalized to the fxn mRNA level in vehicle treated KIKI ( = 100%) or to the FXN (or Fxn) RNA level in DMSO treated cells ( = 1).
Western Blot Analysis
Tissues were homogenized in T-PER tissue protein extraction reagent (Pierce) for total proteins extraction. Histones were purified by acid extraction as described in the protocols from Upstate. Primary antibodies were diluted in Odyssey blocking buffer (Li-Cor) for frataxin (Chemicon) and actin (Sigma) or in PBS for total and acetylated histones antibodies (Upstate) and for human frataxin (Mitosciences). Infrared dye conjugated secondary antibodies (anti-rabbit IRdye800Cw and anti-mouse IRdye680 from Li-Cor) were used to detect and quantify the signal of mouse frataxin / actin using a Li-Cor Odyssey imaging system. Horseradish Peroxidase (HRP) - conjugated secondary antibodies (Santa Cruz Biotechnology) were used to detect the signal of total and acetylated histones and for the human frataxin / Gapdh signal by chemiluminescence.
Chromatin Immunoprecipitation
ChIP was performed as described previously[20]. We adapted the technique for use on fresh brain tissue and were able to test 3 different residues per one hemisphere. For each immunoprecipitation, lysate was incubated with one of the following antibodies (Anti-acetyl-Histone H3 (Lys14): Upstate Biotechnology 07-353; Anti-acetyl-Histone H4 (Lys5): Upstate 07-327; Normal Rabbit IgG: Upstate 12-370). Immunoprecipitated samples were quantified by real-time PCR following the standard curve method. Primers used for the region upstream intronic GAA repeats of Fxn were 5′- ACGACAAAGTCTCCCACAGG-3′ and 5′- GTCCAACAAGGCTTGATTCC-3′. GAPDH primers were: 5′-TGGGTGGAGTGTCCTTTATCC-3′ and 5′-TATGCCCGAGGACAATAAGG-3′.
Supporting Information
Figure S1.
Compound 136 IC50 determination for HDAC1 and HDAC3/NcoR2 (left panel, top/bottom). Compound 136 shows a time-dependent inhibition of HDAC3/NcoR2. IC50s against HDAC3/NcoR2 decrease from 16.8 µM to 560 nM over a period of 3 hours. There is no time-dependent inhibition of HDAC1 with compound 136. Compound 136 is a fast on/off inhibitor of HDAC1 with Ki at 630 nM (right panel, top). Compound 136, however, is a slow-tight binding inhibitor of HDAC3/NcoR2 with Ki at 196 nM (right panel, bottom).
https://doi.org/10.1371/journal.pone.0008825.s001
(2.63 MB TIF)
Figure S2.
Inhibitor 109 IC50s determination for HDAC1 and HDAC3/NcoR2 (left panel, top/bottom). Inhibitor 109 shows a time-dependent inhibition for both HDAC1 and HDAC3/NcoR2. Its IC50s against HDAC1 decrease from 230 nM to 60 nM within an hour. Inhibitor 109 IC50s against HDAC3/NcoR2 decrease from 1 µM to 50 nM over a period of 3 hours. 109 are slow-tight binding inhibitor of both HDAC1 and HDAC3/NcoR2, but the on rate of 109 is faster for HDAC1 than for HDAC3/NcoR2. Compound 109 has a Ki of 32 nM (right panel, top) for HDAC1 and a Ki of 5 nM for HDAC3/NcoR2 (right panel, bottom).
https://doi.org/10.1371/journal.pone.0008825.s002
(2.21 MB TIF)
Figure S3.
Upper panel: Effect of compounds 106, 109 and 136 on PBMCs from subjects with normal GAA repeats (healthy volunteers). FXN mRNA levels were measured after a 48-hour incubation with either 106, 109 and 136 at 10 µM or DMSO (at 0.1%). Quantitative real-time RT-PCR was used to determine relative FXN mRNA levels for each individual condition using GAPDH as control housekeeping gene. DMSO condition was set to value 1 for each individual. Error is represented as the standard deviation of the mean from three dterminations. PBMCs were obtained from donors' blood as described [8]. Middle and lower panels: Changes in local and global acetylation upon removal of HDACi 109. PBMCs from patient P13 were treated with either DMSO or 109 for 48 hours and part of these two samples were collected (samples “DMSO” and “0h”), and the rest washed to remove the inhibitor. Samples were then collected at 6, 12, 24 and 48 hours after washing. At each time point, we measured FXN mRNA levels (upper left panel), occupancy of H4AcK5 on the frataxin gene, upstream of the GAA repeats (upper right panel) and global H3 acetylation (lower left panel, quantified in the lower left panel).
https://doi.org/10.1371/journal.pone.0008825.s003
(2.55 MB TIF)
Acknowledgments
We wish to thank Elodie Carlier for excellent technical assistance. We thank Nick Alaerts for managing blood donations from FRDA patients and all the patients whose participation made this study possible.
Author Contributions
Conceived and designed the experiments: MR JRR JMG MP. Performed the experiments: MR ES CJC. Analyzed the data: MR ES CJC GB SJ JRR JMG MP. Contributed reagents/materials/analysis tools: GB SJ. Wrote the paper: MR ES CJC JRR JMG MP.
References
- 1. Harding AE (1981) Friedreich's ataxia: a clinical and genetic study of 90 families with an analysis of early diagnostic criteria and intrafamilial clustering of clinical features. Brain 104: 589–620.
- 2. Pandolfo M (2009) Introduction. Idebenone in the treatment of Friedreich ataxia. J Neurol 256: Suppl 11–2.
- 3. Campuzano V, Montermini L, Lutz Y, Cova L, Hindelang C, et al. (1997) Frataxin is reduced in Friedreich ataxia patients and is associated with mitochondrial membranes. Hum Mol Genet 6: 1771–1780.
- 4. Sakamoto N, Ohshima K, Montermini L, Pandolfo M, Wells RD (2001) Sticky DNA, a self-associated complex formed at long GAA*TTC repeats in intron 1 of the frataxin gene, inhibits transcription. J Biol Chem 276: 27171–27177.
- 5. Saveliev A, Everett C, Sharpe T, Webster Z, Festenstein R (2003) DNA triplet repeats mediate heterochromatin-protein-1-sensitive variegated gene silencing. Nature 422: 909–913.
- 6. Greene E, Mahishi L, Entezam A, Kumari D, Usdin K (2007) Repeat-induced epigenetic changes in intron 1 of the frataxin gene and its consequences in Friedreich ataxia. Nucleic Acids Res 35: 3383–3390.
- 7. Al-Mahdawi S, Pinto RM, Ismail O, Varshney D, Lymperi S, et al. (2008) The Friedreich ataxia GAA repeat expansion mutation induces comparable epigenetic changes in human and transgenic mouse brain and heart tissues. Hum Mol Genet 17: 735–746.
- 8. Herman D, Jenssen K, Burnett R, Soragni E, Perlman SL, et al. (2006) Histone deacetylase inhibitors reverse gene silencing in Friedreich's ataxia. Nat Chem Biol 2: 551–558.
- 9. Rai M, Soragni E, Jenssen K, Burnett R, Herman D, et al. (2008) HDAC inhibitors correct frataxin deficiency in a Friedreich ataxia mouse model. PLoS One 3: e1958.
- 10. Elgin SC, Grewal SI (2003) Heterochromatin: silence is golden. Curr Biol 13: R895–898.
- 11. Xu WS, Parmigiani RB, Marks PA (2007) Histone deacetylase inhibitors: molecular mechanisms of action. Oncogene 26: 5541–5552.
- 12. Langley B, Gensert JM, Beal MF, Ratan RR (2005) Remodeling chromatin and stress resistance in the central nervous system: histone deacetylase inhibitors as novel and broadly effective neuroprotective agents. Curr Drug Targets CNS Neurol Disord 4: 41–50.
- 13. Mann BS, Johnson JR, Cohen MH, Justice R, Pazdur R (2007) FDA approval summary: vorinostat for treatment of advanced primary cutaneous T-cell lymphoma. Oncologist 12: 1247–1252.
- 14. Xu C, Soragni E, Chou CJ, Herman D, Plasterer HL, et al. (2009) Chemical probes identify a role for histone deacetylase 3 in Friedreich's ataxia gene silencing. Chem Biol 16: 980–989.
- 15. Chou CJ, Herman D, Gottesfeld JM (2008) Pimelic diphenylamide 106 is a slow, tight-binding inhibitor of class I histone deacetylases. J Biol Chem 283: 35402–35409.
- 16. Miranda CJ, Santos MM, Ohshima K, Smith J, Li L, et al. (2002) Frataxin knockin mouse. FEBS Lett 512: 291–297.
- 17. Kawamata N, Chen J, Koeffler HP (2007) Suberoylanilide hydroxamic acid (SAHA; vorinostat) suppresses translation of cyclin D1 in mantle cell lymphoma cells. Blood 110: 2667–2673.
- 18. Luo RX, Postigo AA, Dean DC (1998) Rb interacts with histone deacetylase to repress transcription. Cell 92: 463–473.
- 19. Morrison JF, Walsh CT (1988) The behavior and significance of slow-binding enzyme inhibitors. Adv Enzymol Relat Areas Mol Biol 61: 201–301.